12-month PFS in PD-L1+ (cutoff: ≥5% tumor cells, Dako 28-8) patients (prevalence: ~34%), 81.9 vs. 73.8%; in PD-L1− patients, 64.3 vs. 53.7% Here, CD274 is linked to neoplasm.